50 related articles for article (PubMed ID: 24344400)
1. Clinicopathological Role of Serum-Derived Hyaluronan-Associated Protein (SHAP)-Hyaluronan Complex in Endometrial Cancer.
Yabushita H; Iwasaki K; Kanyama K; Obayashi Y; Zhuo L; Itano N; Kimata K; Wakatsuki A
Obstet Gynecol Int; 2011; 2011():739150. PubMed ID: 21904555
[TBL] [Abstract][Full Text] [Related]
2. Soluble guanylyl cyclase beta1 subunit targets epithelial-to-mesenchymal transition and downregulates Akt pathway in human endometrial and cervical cancer cells.
Acosta LH; Pino MTL; Rocca MV; Cabilla JP
Heliyon; 2024 Jan; 10(1):e23927. PubMed ID: 38205317
[TBL] [Abstract][Full Text] [Related]
3. Clinical and prognostic features of MMP-2 and VEGF in AEG patients.
Zheng QK; Yin Q; Zhang N; Sun ZG
Open Med (Wars); 2021; 16(1):786-794. PubMed ID: 34027107
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of matrix metalloproteinase-2 in endometrial cancer: A systematic review and meta-analysis.
Liu C; Li Y; Hu S; Chen Y; Gao L; Liu D; Guo H; Yang Y
Medicine (Baltimore); 2018 Jul; 97(29):e10994. PubMed ID: 30024495
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of the matrix metalloproteinase 11 gene is a potential biomarker for type 1 endometrial cancer.
Gómez-Macías GS; Garza-Rodríguez ML; Garza-Guajardo R; Monsiváis-Ovalle D; Ancer-Rodríguez J; Barrera-Saldaña HA; Barboza-Quintana O
Oncol Lett; 2018 Jul; 16(1):1073-1078. PubMed ID: 29963184
[TBL] [Abstract][Full Text] [Related]
6. The influence of vascular endothelial growth factor-A and matrix metalloproteinase-2 and -9 in angiogenesis, metastasis, and prognosis of endometrial cancer.
Mahecha AM; Wang H
Onco Targets Ther; 2017; 10():4617-4624. PubMed ID: 29033580
[TBL] [Abstract][Full Text] [Related]
7. Post-transcriptional Regulation of MMP16 and TIMP2 Expression
Rak B; Mehlich D; Garbicz F; Domosud Z; Paskal W; Marczewska JM; Włodarski PK
Cancer Genomics Proteomics; 2017; 14(5):389-401. PubMed ID: 28871006
[TBL] [Abstract][Full Text] [Related]
8. Clinical importance of serum HE4 and MMP2 levels in endometrial cancer patients.
Cymbaluk-Płoska A; Chudecka-Głaz A; Pius-Sadowska E; Sompolska-Rzechuła A; Machaliński B; Surowiec A; Menkiszak J
Onco Targets Ther; 2017; 10():3169-3175. PubMed ID: 28721066
[TBL] [Abstract][Full Text] [Related]
9. Effects of RNA silencing of matrix metalloproteinase-2 on the growth of esophageal carcinoma cells
Shen YG; Feng W; Xu YJ; Jiao NN; Sun DQ; Qu WD; Tang Q; Xiong W; Tang Y; Xia Y; Cai QY; Liu DX; Zhang X; Xu G; Liang GY
Oncol Lett; 2017 Mar; 13(3):1119-1124. PubMed ID: 28454222
[TBL] [Abstract][Full Text] [Related]
10. αvβ6 integrin is required for TGFβ1-mediated matrix metalloproteinase2 expression.
Dutta A; Li J; Fedele C; Sayeed A; Singh A; Violette SM; Manes TD; Languino LR
Biochem J; 2015 Mar; 466(3):525-36. PubMed ID: 25558779
[TBL] [Abstract][Full Text] [Related]
11. Endometrial tumor invasiveness is related to metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expressions.
Graesslin O; Cortez A; Uzan C; Birembaut P; Quereux C; Daraï E
Int J Gynecol Cancer; 2006; 16(5):1911-7. PubMed ID: 17009991
[TBL] [Abstract][Full Text] [Related]
12. Immunoreactivity for TIMP-2 is associated with a favorable prognosis in endometrial carcinoma.
Honkavuori-Toivola M; Talvensaari-Mattila A; Soini Y; Turpeenniemi-Hujanen T; Santala M
Tumour Biol; 2012 Aug; 33(4):935-41. PubMed ID: 22270451
[TBL] [Abstract][Full Text] [Related]
13. Tumoral and stromal expression of MMP-2, MMP-9, MMP-14, TIMP-1, TIMP-2, and VEGF-A in cervical cancer patient survival: a competing risk analysis.
Azevedo Martins JM; Rabelo-Santos SH; do Amaral Westin MC; Zeferino LC
BMC Cancer; 2020 Jul; 20(1):660. PubMed ID: 32669083
[TBL] [Abstract][Full Text] [Related]
14. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
Wei QY; Wu YQ; Fan SQ
Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
[TBL] [Abstract][Full Text] [Related]
15. [Activity of matrix metalloproteinases -2 and -9 (MMP-2 and MMP-9) and content of their tissue inhibitors in endometrial cancer--a preliminary study].
Bogusiewicz M; Stryjecka-Zimmer M; Rechberger T
Ginekol Pol; 2007 May; 78(5):366-72. PubMed ID: 17867327
[TBL] [Abstract][Full Text] [Related]
16. Combination of strong MMP-2 and weak TIMP-2 immunostainings is a significant prognostic factor in endometrial carcinoma.
Honkavuori-Toivola M; Santala M; Soini Y; Turpeenniemi-Hujanen T; Talvensaari-Mattila A
Dis Markers; 2013; 35(4):261-6. PubMed ID: 24344400
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
